|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
From the Thrombosis and Haemostasis Laboratory,
Department of Haematology, Institute of Biomembranes, Van
Creveldkliniek, University Medical Centre, Utrecht University, The
Netherlands; Centre de Traitement des Hémophiles, Hôpital
de Bicêtre, Le Kremlin Bicêtre, France; and Department of
Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands.
Recombinant factor VIIa (rFVIIa) is a novel prohemostatic drug for
patients with hemophilia who have developed inhibitory antibodies. The
postulation has been made that hemophilia is not only a disorder of
coagulation, but that hyperfibrinolysis due to a defective activation
of thrombin activatable fibrinolysis inhibitor (TAFI) might also play a
role. In this in vitro study, the potential of rFVIIa to down-regulate
fibrinolysis via activation of TAFI was investigated. rFVIIa was able
to prolong clot lysis time in plasmas from 17 patients with severe
hemophilia A. The prolongation of clot lysis time by rFVIIa was
completely abolished by addition of an inhibitor of activated TAFI. The
concentration of rFVIIa required for half maximal prolongation of clot
lysis time (Clys1/2-VIIa) varied widely between patients
(median, 73.0 U/mL; range, 10.8-250 U/mL). The concentration of rFVIIa required for half maximal reduction of clotting time
(Cclot1/2-VIIa) was approximately 10-fold lower
than the Clys1/2-VIIa value (median, 8.4 U/mL; range,
1.7-22.5 U/mL). Inhibition of TFPI with a polyclonal antibody
significantly decreased Clys1/2-VIIa values (median, 2.6 U/mL; range, 0-86.9 U/mL), whereas Cclot1/2-VIIa values did
not change (median, 7.2 U/mL; range, 2.2-22.5 U/mL). On addition of 100 ng/mL recombinant full-length TFPI, a nonsignificant increase of
Clys1/2-VIIa values was observed (median, 119.2 U/mL;
range, 12.3-375.0 U/mL), whereas Cclot1/2-VIIa values did
not change (median, 8.8 U/mL; range, 2.6-34.6 U/mL). In conclusion, this study shows that rFVIIa both accelerates clot formation and inhibits fibrinolysis by activation of TAFI in factor VIII-deficient plasma. However, a large variability in antifibrinolytic potential of
rFVIIa exists between patients.
(Blood. 2002;99:175-179) Treatment of patients suffering from hemophilia is
often complicated by the development of inhibitory antibodies. In
approximately 25% to 30% of patients with hemophilia A1
and in approximately 1% to 3% of the patients with hemophilia
B,2 inhibitors develop during their lifetime. A novel way
to treat hemophilia patients with inhibitors is the administration of
recombinant factor VIIa (rFVIIa, NovoSeven, Novo Nordisk, Bagsvaerd,
Denmark).3 rFVIIa has been shown to be a safe and
effective prohemostatic drug during bleeding episodes or
surgery.4,5 Advantages over traditional treatment (ie,
factor concentrates) are the lack of antigenicity and viral safety
of rFVIIa.6,7
rFVIIa exerts its prohemostatic effect via enhancement of the extrinsic
coagulation pathway in a tissue factor-dependent manner.8 On binding of factor VIIa to tissue factor, factor VIIa is able to
activate both factors IX and X, thereby leading to a primary generation
of thrombin. At high concentrations of tissue factor, factor X is the
preferred substrate for the tissue factor-VIIa complex, whereas at low
tissue factor concentrations factor IX is preferably activated (for a
review, see Rapaport and Rao9). The ability of high-dose
rFVIIa to overcome the inhibitory effect of plasma factor VII on
coagulation might play a role in the enhancement of thrombin generation
by rFVIIa.10 After formation of the fibrin clot, thrombin
generation proceeds via the intrinsic pathway through activation of
factor XI by thrombin.11 The secondary burst of thrombin,
which is formed via this factor XI feedback loop, results in the
activation of thrombin activatable fibrinolysis inhibitor (TAFI).12 Activated TAFI down-regulates fibrinolysis by
cleaving C-terminal lysine and arginine residues from partially
degraded fibrin, thereby attenuating tissue-type plasminogen activator (t-PA)-mediated fibrinolysis.13 Activation of TAFI is
stimulated approximately 1200-fold on thrombin binding to the cell
surface receptor thrombomodulin.14
The discovery of TAFI as an important link between coagulation and
fibrinolysis stimulated the development of new concepts on the
regulation of the hemostatic system. A clotting factor deficiency such
as hemophilia A might not only result in defective clot formation, but
also in accelerated clot degradation due to diminished TAFI activation.
Indeed, it has been shown that factor VIII-deficient plasma shows
premature lysis of tissue factor-induced clots due to a lack of TAFI
activation, which could be restored by addition of factor
VIII.15,16 Clinical evidence that supports the hypothesis
of hemophilia A being a defect in both coagulation and fibrinolysis has
been obtained from skin biopsy studies in patients with severe
hemophilia A in which abnormalities in a skin wound could not be
observed until 2 hours after the wound was made.17
Although these abnormalities were initially explained by the decreased
fibrin-forming capacity of these patients, an increased fibrinolytic
potential could also explain these observations. Another indication of
disturbed down-regulation of fibrinolysis in hemophilia is the efficacy
of antifibrinolytic drugs such as tranexamic acid and Alternative mechanisms for the therapeutic effects of rFVIIa have been
proposed. A potential mechanism, hypothesized in the literature,20 involves enhancement of activation of TAFI.
Another possible alternative mechanism involves thrombin formation on activated platelets or monocytes independently of tissue
factor.21,22
In this study, the antifibrinolytic potential of rFVIIa in plasma from
different patients with severe hemophilia A was explored. Also, the
involvement of tissue factor pathway inhibitor (TFPI) on
rFVIIa-mediated clot protection was investigated.
Patients
Materials
The TAFI antigen levels were determined by a sandwich-type enzyme-linked immunosorbent assay (ELISA), using a monoclonal capturing antibody and a polyclonal detection antibody as described.23 TAFI levels were expressed as percentage of pooled normal plasma. TFPI activity levels were determined according to Sandset et al.24 Factor II, VII, and X activity levels were determined by a one-stage clotting assay using factor II- and factor X-deficient plasma from Boeringer Mannheim (Mannheim, Germany), and factor VII-deficient plasma from Helena Laboratories (Beaumont, TX). Thromborel S from Dade Behring (Mannheim, Germany) was used as thromboplastin reagent. Fibrinogen levels were determined according to Clauss,25 using thrombin obtained from Sigma (St Louis, MO). Levels of plasminogen were determined using the Coamatic plasminogen kit from Chromogenix. Soluble thrombomodulin levels were determined using the Asserachrom Thrombomodulin ELISA kit from Diagnostica Stago (Asnières, France). Phospholipid vesicles consisting of 40%
L- Clot lysis assay Lysis of a tissue factor-induced clot by exogenous t-PA was studied by monitoring changes in turbidity during clot formation and subsequent lysis essentially as described previously.29 A mixture of tissue factor (diluted Innovin, final dilution 105 times), CaCl2 (final concentration 17 mM), t-PA (final concentration 30 U/mL; 56 ng/mL), and phospholipid vesicles (final concentration 10 µM) was added to 75 µL citrated plasma. The volume was adjusted to 150 µL with Hepes buffer (25 mM Hepes, 137 mM NaCl, 3.5 mM KCl, 3 mM CaCl2, 0.1% bovine serum albumin, pH 7.4), resulting in a final plasma concentration of 50%. After mixing thoroughly, 100 µL of this mixture was transferred to a microtiter plate and turbidity at 405 nm was measured in time at 37°C in a Spectramax 340 kinetic microplate reader (Molecular Devices, Menlo Park, CA). Clot lysis time was defined as the time from the midpoint of the clear-to-maximum turbid transition, which is defined as clotting time, to the midpoint of the maximum turbid-to-clear transition. To block possible residual factor VIII activity in hemophilic plasma, which did not contain an inhibitor, 10 BU/mL of a polyclonal antibody against human factor VIII was added and preincubated at room temperature for 45 minutes. To assess the contribution of TAFI activation to clot lysis time, experiments were performed in which CPI (25 µg/mL), a specific inhibitor of activated TAFI,13 was added to the plasma. The effect of rFVIIa on fibrinolysis in hemophilic plasma was determined by performing clot lysis assays with factor VIII-deficient plasma to which different concentrations of rFVIIa were added.Statistical analysis Statistical analysis was performed using the GraphPad InStat (GraphPad, San Diego, CA) software package. Statistical significance of the increase in mean clot lysis time on addition of rFVIIa was determined by a repeated measures ANOVA followed by the Dunnett post test. Statistical differences between clotting times in the presence or absence or an inhibitory antibody against tissue factor was determined by the standard t test. Correlations were calculated using the Pearson correlation coefficient. Statistical significance between differences in clot lysis time (Clys1/2-VIIa) or clotting time (Cclot1/2-VIIa) on manipulation of TFPI was calculated by a repeated measures ANOVA followed by the Tukey post test. P < .05 was considered statistically significant.
rFVIIa mediates down-regulation of fibrinolysis and acceleration of clot formation in factor VIII-deficient plasma To investigate whether rFVIIa restores down-regulation of fibrinolysis in factor VIII-deficient plasma, clot lysis assays were performed using plasma from 17 patients with severe hemophilia A in the presence of different concentrations of rFVIIa. A polyclonal inhibitory antibody to human factor VIII was added to the plasma samples in which no inhibitor was present, because a previous study showed that as little as 0.01% of factor VIII present in pooled normal plasma is sufficient to completely restore down-regulation of fibrinolysis in factor VIII-deficient plasma.16 A typical example of the effect of rVIIa on clot lysis time in hemophilic plasma is shown in Figure 1A. rFVIIa was able to prolong clot lysis time in all patient samples. The rFVIIa-mediated prolongation of clot lysis time could be completely abolished by the addition of a specific inhibitor of activated TAFI (CPI). Figure 1B shows mean clot lysis times for the 17 patient samples at increasing concentrations of rFVIIa. At rFVIIa concentrations of 31.3 U/mL and higher the increase in clot lysis time was statistically significant (P < .01). From the rFVIIa titration curves the concentrations of rFVIIa required for half maximal prolongation of clot lysis time (Clys1/2-VIIa) were determined as shown in Figure 1C.
A wide variation of Clys1/2-VIIa values was observed as
shown in Figure 2A (median, 73.0 U/mL;
range, 10.7-250.0 U/mL). Clys1/2-VIIa values were similar
in plasma samples from patients without (median, 73.0 U/mL; range,
17.4-185.9 U/mL) and with (median, 81.8 U/mL; range 10.7-250.0 U/mL)
inhibitory antibodies. To examine whether the antifibrinolytic
potential of rVIIa remained constant over time in a single patient,
Clys1/2-VIIa values of 2 unrelated patients were determined
in 4 plasma samples collected at intervals of approximately 3 months.
These experiments showed that Clys1/2-VIIa values remained
constant in a period of 1 year (patient 1, range 238-267 U/mL; patient
2, range 91-150 U/mL).
To investigate the effect of tissue factor concentration on Clys1/2-VIIa values, clot lysis assays were performed using plasma of a single patient in which coagulation was initiated by increasing amounts of tissue factor. Clys1/2-VIIa was 85 U/mL at the tissue factor dilution used throughout this study. When the tissue factor concentration was doubled or quintupled, Clys1/2-VIIa values decreased to 26 and 11 U/mL, respectively. Correlation of Clys1/2-VIIa values with levels of several plasma proteins To study possible parameters that influence Clys1/2-VIIa values, levels of several plasma proteins were measured and the correlation with Clys1/2-VIIa values was determined. Clys1/2-VIIa values were not correlated with TFPI activity (r = 0.190, P = .468), TAFI antigen (r = 0.089, P = .729), soluble thrombomodulin antigen (r = 0.032, P = .895), fibrinogen (r = 0.054, P = .861), factor II activity (r = 0.071, P = .785), factor VII activity (r = 0.286, P = .265), factor X activity (r = 0.302, P = .238), and plasminogen activity (r = 0.032, P = .902) levels.To exclude the possibility that differences in trace amounts of factor VIII activity left in the plasma samples account for the large variation in Clys1/2-VIIa values, an experiment was performed using a plasma sample from a patient with severe hemophilia A due to an intron 22 gene inversion, who did not receive any treatment for more than a year. The plasma in this patient was considered to completely lack factor VIII activity. Clys1/2-VIIa values were determined in this plasma sample in the presence of the polyclonal inhibitory antibody in the absence or presence of 1 mU/mL factor VIII, which represents 0.1% of the factor VIII found in pooled normal plasma. Clys1/2-VIIa did not change on addition of factor VIII, indicating sufficient inhibition of 0.1% factor VIII by the antibody (data not shown). Improvement of clot formation requires around 10-fold less rFVIIa than improvement of fibrinolysis In all patients, a significant reduction in clotting time on addition of rFVIIa was observed. A typical example of the effect of rFVIIa on clotting time is shown in Figure 1D. Cclot1/2-VIIa values were defined as the concentration of rVIIa required to half-maximally reduce clotting time. Cclot1/2-VIIa values were approximately 10-fold lower than Clys1/2-VIIa values as shown in Figure 2B (median, 8.4 U/mL; range, 1.7-22.5 U/mL). Cclot1/2-VIIa values were not correlated with Clys1/2-VIIa values (r = 0.187, P = .470). Cclot1/2-VIIa for pooled normal plasma was 9.9 U/mL.Cclot1/2-VIIa values correlate with endogenous factor VII levels The Cclot1/2-VIIa values were positively correlated with endogenous factor VII levels as shown in Figure 3 (r = 0.653, P < .005). Cclot1/2-VIIa values were not correlated with plasma levels of factor X (r = 0.311, P = .223), factor II (r = 0.164, P = .530), and fibrinogen (r = 0.206, P = .499).
Tissue factor dependency of clot formation in hemophilic plasma To investigate whether clot formation in factor VIII-deficient plasma was completely dependent on tissue factor, clot lysis assays were performed using plasma samples from 4 patients (all with inhibitory antibodies against factor VIII) in the presence of increasing concentrations of rFVIIa and in the presence or absence of an inhibitory antibody against tissue factor (500 µg/mL). As shown in Figure 4, clot formation was significantly inhibited (clotting time > 30 minutes) on inhibition of tissue factor. When rFVIIa was added to the plasma, clotting did occur during the time span of our experiment when tissue factor was inhibited. Inhibition of tissue factor attenuated clot formation at all rFVIIa concentrations tested. However, at 125 and 250 U/mL rFVIIa the increase in clotting time on inhibition of tissue factor was no longer statistically significant.
Effects of modulation of TFPI on Clys1/2-VIIa and Cclot1/2-VIIa values The effect of TFPI on Clys1/2-VIIa and Cclot1/2-VIIa values was investigated in all patient samples. As shown in Figure 5A, addition of rFL-TFPI resulted in an increase in Clys1/2-VIIa values (median, 119.2 U/mL; range, 12.3-375 U/mL), but this did not reach statistical significance. Inhibition of TFPI by an inhibitory antibody resulted in a significant decrease of Clys1/2-VIIa values (median, 2.6 U/mL; range, 0-86.9 U/mL; P < .05).
As shown in Figure 5B, addition of rFL-TFPI did not change Cclot1/2-VIIa values (median, 7.2 U/mL; range, 2.2-20.5 U/mL). Also addition of a blocking antibody against TFPI did not change Cclot1/2-VIIa values (median, 8.8 U/mL; range, 2.6-34.6 U/mL). However, clotting times in the absence of rFVIIa were decreased by addition of a blocking antibody against TFPI, whereas clotting times in the absence of rFVII increased by addition of rFL-TFPI (data not shown).
This in vitro study shows that rFVIIa both accelerates clot formation and inhibits fibrinolysis by activation of TAFI in factor VIII-deficient plasma. In agreement with previous studies, we have shown a lack of TAFI activation in plasma from patients with severe hemophilia A at low tissue factor concentrations, implicating that hemophilia is a disorder of both clot formation and down-regulation of clot breakdown. In a previous study, we showed that as little as 0.01% of the amount of factor VIII present in pooled normal plasma completely restores TAFI-mediated down-regulation of fibrinolysis in factor VIII-deficient plasma.16 Here, we showed that high rFVIIa levels are required for inhibition of fibrinolysis. Values required for half maximal effect range from therapeutic (10.7 U/mL) to supratherapeutic (250 U/mL) levels. We have not been able to determine specific factors that determine Clys1/2-VIIa values. We speculate that the antifibrinolytic potential of rVIIa is determined by a combination of both thrombin-generating capacity and plasma fibrinolytic potential. We have shown that the amount of rFVIIa required to restore fibrinolysis is dependent on the concentration of tissue factor. The efficacy of a certain dose of rFVIIa in a patient is probably highly dependent on the site of injury and the extent of vascular damage. It is likely also that in vivo rFVIIa is more effective in down-regulation of the fibrinolytic system at wounds where large amounts of tissue factor are exposed. Another important factor in the efficacy of rFVIIa is the amount of thrombomodulin present. Thrombomodulin is capable of enhancing TAFI activation by approximately 3 orders of magnitude.14 However, a high concentration of thrombomodulin down-regulates TAFI activation by protein C activation.30 Thus, it is likely that both tissue factor and thrombomodulin present at the site of injury determine the antifibrinolytic potential of rFVIIa in a patient with hemophilia A. The regulatory effect of TFPI in rVIIa-mediated inhibition of fibrinolysis becomes evident on evaluation of Clys1/2-VIIa values, which are determined in the presence of a blocking antibody against TFPI. In the absence of the inhibitory activity of TFPI, little rFVIIa is needed to restore fibrinolysis, and in some patients fibrinolysis was already maximally inhibited in the absence of rFVIIa. The addition of rFL-TFPI did not lead to a significant inhibition of the antifibrinolytic effect of rFVIIa, probably because TFPI concentrations present in plasma were nearly saturating at the low tissue factor concentrations used in our assay. The effect of rFVIIa on clot formation was more pronounced than the effect on TAFI activation; the levels of rFVIIa required to half maximally reduce clot formation were approximately 10-fold lower than those required to half maximally inhibit fibrinolysis. Moreover Clys1/2-VIIa values were not correlated with Cclot1/2-VIIa values. This indicates that primary and secondary thrombin formation in factor VIII-deficient plasma are differently regulated processes. This phenomenon is supported by the observation that modulation of TFPI activity clearly affects Clys1/2-VIIa values, whereas Cclot1/2-VIIa values are unchanged. The inhibitory activity of TFPI on clot formation is overruled by rVIIa. This might be due to kinetic limitations combined with the rate-limiting concentration of factor Xa. The thrombin generation that occurs after formation of the fibrin clot is efficiently inhibited by TFPI even in the presence of rVIIa, as inhibition of TFPI markedly reduces Clys1/2-VIIa values. The hypothesis that primary and secondary thrombin formation in our system are differently regulated processes is further supported by the observation that endogenous factor VII levels positively correlate with Cclot1/2-VIIa but not with Clys1/2-VIIa values. The correlation of endogenous factor VII levels with Cclot1/2-VIIa corresponds to the inhibitory activity of zymogen factor VII on tissue factor-induced coagulation as described by van 't Veer et al.10 Apparently this inhibitory activity is not important for secondary thrombin generation. In conclusion, the efficacy of rFVIIa infusion in patients with hemophilia who developed inhibitory antibodies may be explained by a combination of the following factors: (1) enhancement of clot formation via the tissue factor pathway, possibly by overruling the inhibitory activity of zymogen factor VII, and (2) down-regulation of fibrinolysis by TAFI activation, which contributes to the stability of the clot. However, until now we have had no evidence that the antifibrinolytic effect of rFVIIa also occurs in the in vivo situation. More sophisticated techniques for TAFI activation in vivo will be required to address this question. Whether the in vitro variations in antifibrinolytic potential of rFVIIa may have clinical relevance (eg, in predicting clinical efficacy of rFVIIa in patients with severe hemophilia) will be investigated in future studies.
The authors would like to thank Drs U. Hedner and M. Kjalke for their generous gift of rFVIIa, rFL-TFPI, and the antibodies against factor VIII and tissue factor, and Dr W. Kisiel for his generous gift of the antibody against TFPI.
Submitted June 15, 2001; accepted August 27, 2001.
Supported in part by an unrestricted educational grant of Novo Nordisk, and a grant from the Netherlands Heart Foundation (grant 96.088). J.C.M.M. is an Established Investigator of the Netherlands Heart Foundation (grant D96.021).
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Ton Lisman, Thrombosis and Haemostasis Laboratory, Dept of Haematology, G03.647, University Medical Center, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands; e-mail: j.a.lisman{at}lab.azu.nl.
1. Hoyer LW. The incidence of factor VIII inhibitors in patients with severe haemophilia A. In: Aledort LM,Hoyer LW,Lusher JM,Reisner HM,White CG, eds. Inhibitors to Coagulation Factors. New York: Plenum Press; 1995:35-45. 2. High KA. Factor IX: molecular structure, epitopes, and mutations associated with inhibitor formation. In: Aledort LM,Hoyer LW,Lusher JM,Reisner HM,White CG, eds. Inhibitors to Coagulation Factors. New York: Plenum Press; 1995:79-86. 3. Hedner U. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa. Thromb Haemost. 1999;82:531-539[Medline] [Order article via Infotrieve]. 4. Ingerslev J. Efficacy and safety of recombinant factor VIIa in the prophylaxis of bleeding in various surgical procedures in hemophilic patients with factor VIII and factor IX inhibitors. Semin Thromb Hemost. 2000;26:425-432[CrossRef][Medline] [Order article via Infotrieve]. 5. Negrier C, Hay CR. The treatment of bleeding in hemophilic patients with inhibitors with recombinant factor VIIa. Semin Thromb Hemost. 2000;26:407-412[CrossRef][Medline] [Order article via Infotrieve]. 6. Nicolaisen EM. Antigenicity of activated recombinant factor VII followed through nine years of clinical experience. Blood Coagul Fibrinolysis. 1998;9(suppl 1):S119-S123.
7.
Lund-Hansen T.
NovoSeven 8. ten Cate H, Bauer KA, Levi M, et al. The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor. J Clin Invest. 1993;92:1207-1212. 9. Rapaport SI, Rao LV. The tissue factor pathway: how it has become a "prima ballerina." Thromb Haemost. 1995;74:7-17[Medline] [Order article via Infotrieve].
10.
van 't Veer C, Golden NJ, Mann KG.
Inhibition of thrombin generation by the zymogen factor VII: implications for the treatment of hemophilia A by factor VIIa.
Blood.
2000;95:1330-1335
11.
von dem Borne PAKr, Meijers JCM, Bouma BN.
Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis.
Blood.
1995;86:3035-3042 12. von dem Borne PAKr, Bajzar L, Meijers JCM, Nesheim ME, Bouma BN. Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis. J Clin Invest. 1997;99:2323-2327[Medline] [Order article via Infotrieve]. 13. Redlitz A, Tan AK, Eaton DL, Plow EF. Plasma carboxypeptidases as regulators of the plasminogen system. J Clin Invest. 1995;96:2534-2538.
14.
Bajzar L, Morser J, Nesheim M.
TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex.
J Biol Chem.
1996;271:16603-16608
15.
Broze GJ Jr, Higuchi DA.
Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma.
Blood.
1996;88:3815-3823 16. Mosnier LO, Lisman T, van den Berg HM, Nieuwenhuis HK, Meijers JCM, Bouma BN. The defective down regulation of fibrinolysis in haemophilia A can be restored by increasing the TAFI plasma concentration. Thromb Haemost. 2001;86:1035-1039[Medline] [Order article via Infotrieve]. 17. Sixma JJ, van den Berg A. The haemostatic plug in haemophilia A: a morphological study of haemostatic plug formation in bleeding time skin wounds of patients with severe haemophilia A. Br J Haematol. 1984;58:741-753[Medline] [Order article via Infotrieve]. 18. Sindet-Pedersen S, Ingerslev J, Ramstrom G, Blomback M. Management of oral bleeding in haemophilic patients. Lancet. 1988;2:566[Medline] [Order article via Infotrieve]. 19. Reid WO, Lucase ON, Francisco S, Geisler PH, Erslev AJ. The use of epsilon aminocaproic acid in the management of dental extractions in the hemophiliac. Am J Med Sci. 1964;248:184-188[Medline] [Order article via Infotrieve]. 20. Hedner U. NovoSeven as a universal haemostatic agent. Blood Coagul Fibrinolysis. 2000;11(suppl 1):S107-S111.
21.
Hoffman M, Monroe DM, Roberts HR.
Human monocytes support factor X activation by factor VIIa, independent of tissue factor: implications for the therapeutic mechanism of high-dose factor VIIa in hemophilia.
Blood.
1994;83:38-42 22. Monroe DM, Hoffman M, Olivier JA, Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol. 1997;99:542-547[CrossRef][Medline] [Order article via Infotrieve]. 23. Mosnier LO, von dem Borne PAKr, Meijers JCM, Bouma BN. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost. 1998;80:829-835[Medline] [Order article via Infotrieve]. 24. Sandset PM, Abildgaard U, Pettersen M. A sensitive assay of extrinsic coagulation pathway inhibitor (EPI) in plasma and plasma fractions. Thromb Res. 1987;47:389-400[CrossRef][Medline] [Order article via Infotrieve]. 25. Clauss A. Gerinnungsphysiologische snellmethode zur bestimmung des fibrinogens. Acta Haemat. 1957;17:237-246[Medline] [Order article via Infotrieve]. 26. Brunner J, Skrabal P, Hauser H. Single bilayer vesicles prepared without sonication. Physico-chemical properties. Biochim Biophys Acta. 1976;455:322-331[Medline] [Order article via Infotrieve]. 27. Van Wijnen M, Stam JG, Chang GTG, et al. Characterization of mini-protein S, a recombinant variant of protein S that lacks the sex hormone binding globulin-like domain. Biochem J. 1998;330:389-396. 28. Rouser G, Fkeischer S, Yamamoto A. Two dimensional then layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots. Lipids. 1970;5:494-496[Medline] [Order article via Infotrieve]. 29. Lisman T, Leebeek FW, Mosnier LO, et al. Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology. 2001;121:131-139[CrossRef][Medline] [Order article via Infotrieve]. 30. Mosnier LO, Meijers JC, Bouma BN. Regulation of fibrinolysis in plasma by TAFI and protein C is dependent on the concentration of thrombomodulin. Thromb Haemost. 2001;85:5-11[Medline] [Order article via Infotrieve].
© 2002 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  C. Weeterings, P. G. de Groot, J. Adelmeijer, and T. Lisman The glycoprotein Ib-IX-V complex contributes to tissue factor-independent thrombin generation by recombinant factor VIIa on the activated platelet surface Blood, October 15, 2008; 112(8): 3227 - 3233. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. J. Bowman, W. E. Uber, M. R. Stroud, L. R. Christiansen, J. Lazarchick, A. J. Crumbley III, J. M. Kratz, J. M. Toole, F. A. Crawford Jr, and J. S. Ikonomidis Use of Recombinant Activated Factor VII Concentrate to Control Postoperative Hemorrhage in Complex Cardiovascular Surgery Ann. Thorac. Surg., May 1, 2008; 85(5): 1669 - 1677. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. Mannucci and M. Levi Prevention and Treatment of Major Blood Loss N. Engl. J. Med., May 31, 2007; 356(22): 2301 - 2311. [Full Text] [PDF]
|
|
|
|
 |
|
 L. O. Mosnier and B. N. Bouma Regulation of Fibrinolysis by Thrombin Activatable Fibrinolysis Inhibitor, an Unstable Carboxypeptidase B That Unites the Pathways of Coagulation and Fibrinolysis Arterioscler. Thromb. Vasc. Biol., November 1, 2006; 26(11): 2445 - 2453. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Monroe and M. Hoffman What Does It Take to Make the Perfect Clot? Arterioscler. Thromb. Vasc. Biol., January 1, 2006; 26(1): 41 - 48. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Lisman, P. G. de Groot, J. C.M. Meijers, and F. R. Rosendaal Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis Blood, February 1, 2005; 105(3): 1102 - 1105. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Colucci, B. M. Binetti, A. Tripodi, V. Chantarangkul, and N. Semeraro Hyperprothrombinemia associated with prothrombin G20210A mutation inhibits plasma fibrinolysis through a TAFI-mediated mechanism Blood, March 15, 2004; 103(6): 2157 - 2161. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Lisman, J. Adelmeijer, H. F. G. Heijnen, and P. G. de Groot Recombinant factor VIIa restores aggregation of {alpha}IIb{beta}3-deficient platelets via tissue factor-independent fibrin generation Blood, March 1, 2004; 103(5): 1720 - 1727. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Nesheim Thrombin and Fibrinolysis Chest, September 1, 2003; 124(3_suppl): 33S - 39S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Lisman, S. Moschatsis, J. Adelmeijer, H. K. Nieuwenhuis, and P. G. De Groot Recombinant factor VIIa enhances deposition of platelets with congenital or acquired alpha IIbbeta 3 deficiency to endothelial cell matrix and collagen under conditions of flow via tissue factor-independent thrombin generation Blood, March 1, 2003; 101(5): 1864 - 1870. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. R. Bijsterveld, A. H. Moons, S. M. Boekholdt, B. E. van Aken, H. Fennema, R. J.G. Peters, J. C.M. Meijers, H. R. Buller, and M. Levi Ability of Recombinant Factor VIIa to Reverse the Anticoagulant Effect of the Pentasaccharide Fondaparinux in Healthy Volunteers Circulation, November 12, 2002; 106(20): 2550 - 2554. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2002 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
-aminocaproic
acid in controlling bleedings in regions of the body with high
fibrinolytic activity (eg, the oral cavity).
70°C
until use.
-dioleoylphosphatidylcholine, 20%
L-
virus safety.
Haemostasis.
1996;26(suppl 1):96-97.